Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Sarcoma 1NET 1Genitourinary 1Endocrine 1Dermatologic 1CNS 1

Conditions

Colorectal Neoplasms 315Pancreatic Neoplasms 186Carcinoma, Hepatocellular 116Stomach Neoplasms 110Colonic Neoplasms 84Esophageal Neoplasms 80Carcinoma, Non-Small-Cell Lung 80Breast Neoplasms 78Rectal Neoplasms 75Ovarian Neoplasms 62Neoplasm Metastasis 59Lung Neoplasms 58Neoplasms 54Cholangiocarcinoma 53Melanoma 45Liver Neoplasms 45Gastrointestinal Neoplasms 43Prostatic Neoplasms 42Biliary Tract Neoplasms 37Endometrial Neoplasms 33Squamous Cell Carcinoma of Head and Neck 31Sarcoma 29Carcinoma, Renal Cell 29Esophageal Squamous Cell Carcinoma 27Uterine Cervical Neoplasms 26Adenocarcinoma Of Esophagus 24Head and Neck Neoplasms 23Urinary Bladder Neoplasms 22Small Cell Lung Carcinoma 20Gastrointestinal Stromal Tumors 17

Interventions

durvalumab 1Immunotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Neoplasms, Glandular and Epithelial × Gastrointestinal × 30 days × Clear all
NCT05063565 2026-06-01

ROWAN

Boston Scientific Corporation

Phase 2 Active not recruiting
100 enrolled
Gastrointestinal

Adenocarcinoma, Carcinoma, Digestive System Diseases, Digestive System Neoplasms, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial

NCT07377487 2026-05-22

INDIGO

Boston Scientific Corporation

Phase NA Recruiting
51 enrolled
EndocrineGastrointestinalNET

Carcinoma, Colonic Diseases, Digestive System Diseases, Digestive System Neoplasms, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Colorectal Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT06794073 2026-05-11

Efficacy and Safety of Multimodal Ablation Combined With PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of Unresectable Primary Hepatocellular Carcinoma: A Single-Arm, Single-Center Clinical Study

Shanghai Zhongshan Hospital

Phase NA Recruiting
17 enrolled
Gastrointestinal

Adenocarcinoma, Digestive System Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasms, Glandular and Epithelial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡